SynthesisJournal of hypertension2017
In-utero exposure to antihypertensive medication and neonatal and child health outcomes: a systematic review.
Synthesis in Journal of hypertension, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03873194 (Use of Meditation as a Complementary Therapy in the Treatment of Gestational Hypertension), which is not on this map. Cited by 34 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Use of Meditation as a Complementary Therapy in the Treatment of Gestational Hypertension
Who cites it
34 citing papers in PubMed, 4 syntheses or guidelines pooled it, 79 citations in OpenAlex.
- Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care.Canadian family physician Medecin de famille canadien · 2025Guideline
- Guideline
- Hypertension Canada guideline for the diagnosis and treatment of hypertension in adults in primary care.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2025Guideline
- Guide de pratique clinique en soins de première ligne d'Hypertension Canada pour le diagnostic et le traitement de l'hypertension artérielle chez les adultes.Canadian family physician Medecin de famille canadienGuideline
- Prenatal exposure to antihypertensive medication: A systematic review of neurodevelopmental and educational outcomes.JCPP advances · 2026Article
- Genetically Informed Research Designs in Perinatal Pharmacoepidemiology: A Methodological Overview.Drug safety · 2026Review
- Article
- Pharmacoepigenomic effects of anti-hypertensive drugs on DNA methylation and its implication to drug response and side effects.Epigenomics · 2025Article
- Article
- Pharmacotherapeutic options for the treatment of hypertension in pregnancy.Expert opinion on pharmacotherapy · 2024Review
- Effects of hypertension and use of antihypertensive drugs in pregnancy on the risks of childhood cancers in Taiwan.Cancer causes & control : CCC · 2024Article
- Pregnancy Arrhythmias: Management in the Emergency Department and Critical Care.Journal of clinical medicine · 2024Review
- Antihypertensive therapy during pregnancy: the prescription pattern in Italy.Frontiers in pharmacology · 2024Article
- The contribution of hypertensive disorders of pregnancy to late preterm and term admissions to neonatal units in the UK 2012-2020 and opportunities to avoid admission: A population-based study using the National Neonatal Research Database.BJOG : an international journal of obstetrics and gynaecology · 2024Article
- Case series of catheter-based arrhythmia ablation in 13 pregnant women.Clinical cardiology · 2023Article
- Maternal and childhood medical history and the risk of childhood brain tumours: a case-control study in Ontario, Canada.British journal of cancer · 2023Article
- Comparing Intravenous Labetalol and Intravenous Hydralazine for Managing Severe Gestational Hypertension.Cureus · 2023Article
- Treatment and practical considerations of diabetic kidney disease.Frontiers in medicine · 2023Review
- Hypertension Across a Woman's Life Cycle.Current hypertension reports · 2022Review
- Supraventricular arrhythmia in pregnancy.Heart (British Cardiac Society) · 2022Review
Corrections and comments
- Commented on by
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundAlthough medication is generally avoided wherever possible during pregnancy, pharmacotherapy is required for the treatment of pregnancy associated hypertension, which remains a leading cause of maternal and fetal morbidity and mortality. The long-term effects to the child of in-utero exposure to antihypertensive agents remains largely unknown.
objectiveThe aim of this study was to systematically review published studies on adverse outcomes to the child associated with in-utero exposure to antihypertensive medications.
methodsOVID, Scopus, EBSCO Collections, the Cochrane Library, and Web of Science databases were searched for relevant publications published between January 1950 and October 2016 and a total of 688 potentially eligible studies were identified.
resultsFollowing review, 47 primary studies were eligible for inclusion. The Critical Appraisal Skills Programme checklist was used to assess study quality. Five studies were of excellent quality; the remainder were either mediocre or poor. Increased risk of low birth weight, low size for gestational age, preterm birth, and congenital defects following in-utero exposure to all antihypertensive agents were identified. Two studies reported an increased risk of attention deficit hyperactivity disorder following exposure to labetalol, and an increased risk of sleep disorders following exposure to methyldopa and clonidine.
conclusionThe current systematic review demonstrates a paucity of relevant published high-quality studies. A small number of studies suggest possible increased risk of adverse child health outcomes; however, most published studies have methodological weaknesses and/or lacked statistical power thus preventing any firm conclusions being drawn.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.